TSX Exchange Symbol: RVX
ORLANDO, FL, Nov. 5 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX)
is pleased to announce today key scientific data was presented in an oral
presentation highlighting the novel features of RVX-208, at the American Heart
Association Scientific Meetings. The presentation titled "Oral Administration
of Compound RVX-208 Increases Serum Levels of ApoA-I and Improves High-Density
Lipoprotein-Mediated Cholesterol Efflux in African Green Monkeys" was
presented by Dr. Jacques Genest.
Dr. Jacques Genest, MD, Director of the Division of Cardiology at McGill
University Health Centre/Royal Victoria Hospital said, "We were excited about
this data and felt that it should be presented at this prestigious conference.
Resverlogix's novel drug demonstrated the ability to increase the production
of ApoA-I and functional HDL. Notably we saw increases in pre beta HDL sub
particles, which improve HDL's ability to mediate cholesterol efflux."
"We are very pleased to have our data presented at one of the most
prestigious conferences for cardiovascular disease," stated Dr. Jan Johansson,
MD, Ph.D., Senior Vice President, Clinical Affairs of Resverlogix. "Our small
molecule, RVX-208, by virtue of increasing endogenous production of ApoA-I and
functional HDL has huge potential to address the unmet medical need of
cardiovascular disease," added Dr Johansson.
Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the bodies natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e. transport of
peripheral cholesterol including that of the vessel wall to the liver for
processing. In multiple human and animal studies over-expression or repeated
infusion of ApoA-I inhibit progression and induce regression of
atherosclerosis in animals and humans. In his presentation Dr. Genest
discussed the effects of oral administration of RVX-208 on serum ApoA-I
levels, HDL subspecies distribution and the functional improvements of serum
to promote cellular cholesterol efflux from vulnerable plaque cells. The mere
fact that the data is based on African Green monkeys in a context of
dose-response makes it predictive for similar treatment effects in humans.
About Cardiovascular Disease (CVD)
CVD can be generally defined as any abnormal condition characterized by
dysfunction of the heart and blood vessels. CVD includes atherosclerosis
(especially coronary heart disease which can lead to heart attacks),
cerebrovascular disease (stroke), and hypertension (high blood pressure). The
underlying cause of most CVD is a gradual clogging of the arteries
(atherosclerosis) that supply blood to the heart, brain and other vital
The American Heart Association estimates that almost 80 million American
Adults have one or more types of cardiovascular disease. CVD remains the
number one killer of developed nations. Nearly 2400 Americans die each day
from cardiovascular disease - that is 1 person will die every 36 seconds.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's and other
vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as cancer and
fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: please contact: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495,
Email: Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email:
Sarah@resverlogix.com, Website: www.resverlogix.com